Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1987 1
1988 2
1989 4
1990 2
1991 2
1992 2
1993 1
1997 1
1998 5
2005 1
2006 1
2007 1
2008 1
2010 1
2011 2
2012 2
2016 1
2017 1
2018 1
2020 1
2021 2
2022 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Neuropsychological dysfunction in sleep apnea.
Greenberg GD, Watson RK, Deptula D. Greenberg GD, et al. Among authors: deptula d. Sleep. 1987 Jun;10(3):254-62. doi: 10.1093/sleep/10.3.254. Sleep. 1987. PMID: 3629088
Benzodiazepine use and crash risk in older patients.
Pomara N, Tun H, DaSilva D, Deptula D, Greenblatt DJ. Pomara N, et al. Among authors: deptula d. JAMA. 1998 Jan 14;279(2):113-4; author reply 115. JAMA. 1998. PMID: 9440655 No abstract available.
41 results